Building B
11 HaMenofim Street
Herzliya 4672562
Israel
972 9 799 6183
https://www.neurosense-tx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 14
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Alon Ben-Noon | Co-Founder, CEO & Director | 619k | N/A | 1979 |
Mr. Or Eisenberg | Chief Financial Officer | 378k | N/A | 1981 |
Dr. Ferenc Tracik M.D. | Chief Medical Officer | 513k | N/A | 1964 |
Ms. Hagit Binder | Chief Operation Officer | N/A | N/A | 1978 |
Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer | N/A | N/A | 1979 |
Ms. Yael Barak | VP of Quality & Compliance | N/A | N/A | 1970 |
Ms. Keren Pushett | Head of HR | N/A | N/A | N/A |
Mr. Eidan Loushi | C.R.A. | N/A | N/A | N/A |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
El ISS Governance QualityScore de NeuroSense Therapeutics Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.